4DMedical Expands Global Reach with New Healthcare Agreements

4DMedical Limited (ASX: 4DX) has signed three major agreements that expand its footprint across Australia and Brazil in lung health screening and clinical imaging. In partnership with a leading global pharmaceutical company, the company has launched a lung health screening program in Brazil, starting at Hospital Madre Teresa, with capacity for up to 10,000 scans by August 2026. The program initially spans eight hospitals and focuses on lung cancer screening and detecting incidental conditions such as coronary artery calcification and COPD.

In Australia, Royal Melbourne Hospital has become the first public hospital and Academic Medical Centre to pilot 4DMedical’s full suite of advanced lung ventilation analysis tools, running through December 2025 as part of the National Lung Cancer Screening Program (NLCSP). Additionally, 4DMedical has entered a multi-year contract with Spectrum Medical Imaging in NSW, extending to June 2027, to integrate its SaaS lung imaging solutions into the NLCSP. These collaborations highlight 4DMedical’s growing global reputation and role in transforming respiratory diagnostics.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com